Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis

Paul J. Davis, Hung Yun Lin, Thangirala Sudha, Murat Yalcin, Heng Yuan Tang, Aleck Hercbergs, John T. Leith, Mary K. Luidens, Osnat Ashur-Fabian, Sandra Incerpi, Shaker A. Mousa

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

The extracellular domain of integrin avB3 contains a receptor for thyroid hormone and hormone analogs. The integrin is amply expressed by tumor cells and dividing blood vessel cells. The proangiogenic properties of thyroid hormone and the capacity of the hormone to promote cancer cell proliferation are functions regulated nongenomically by the hormone receptor on avB3. An L-thyroxine (T4) analog, tetraiodothyroacetic acid (tetrac), blocks binding of T4 and 3,5,3'-triiodo-L-thyronine (T3) by avB3 and inhibits angiogenic activity of thyroid hormone. Covalently bound to a 200 nm nanoparticle that limits its activity to the cell exterior, tetrac reformulated as Nanotetrac has additional effects mediated by avB3 beyond the inhibition of binding of T4 and T3 to the integrin. These actions of Nanotetrac include disruption of transcription of cell survival pathway genes, promotion of apoptosis by multiple mechanisms, and interruption of repair of double-strand deoxyribonucleic acid breaks caused by irradiation of cells. Among the genes whose expression is suppressed by Nanotetrac are EGFR, VEGFA, multiple cyclins, catenins, and multiple cytokines. Nanotetrac has been effective as a chemotherapeutic agent in preclinical studies of human cancer xenografts. The low concentrations of avB3 on the surface of quiescent nonmalignant cells have minimized toxicity of the agent in animal studies.

Original languageEnglish
Pages (from-to)1619-1624
Number of pages6
JournalOncoTargets and Therapy
Volume7
DOIs
Publication statusPublished - 2014

Fingerprint

Integrins
Hormones
Thyroid Hormones
Neoplasms
Thyronines
Catenins
Thyroid Hormone Receptors
Cyclins
Thyroxine
Heterografts
Nanoparticles
Blood Vessels
Blood Cells
Cell Survival
Cell Proliferation
Apoptosis
Cytokines
Gene Expression
DNA
Genes

Keywords

  • Antiangiogenesis
  • Integrin
  • Proapoptosis
  • Thyroid hormone
  • Thyroxine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. / Davis, Paul J.; Lin, Hung Yun; Sudha, Thangirala; Yalcin, Murat; Tang, Heng Yuan; Hercbergs, Aleck; Leith, John T.; Luidens, Mary K.; Ashur-Fabian, Osnat; Incerpi, Sandra; Mousa, Shaker A.

In: OncoTargets and Therapy, Vol. 7, 2014, p. 1619-1624.

Research output: Contribution to journalReview article

Davis, PJ, Lin, HY, Sudha, T, Yalcin, M, Tang, HY, Hercbergs, A, Leith, JT, Luidens, MK, Ashur-Fabian, O, Incerpi, S & Mousa, SA 2014, 'Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis', OncoTargets and Therapy, vol. 7, pp. 1619-1624. https://doi.org/10.2147/OTT.S67393
Davis, Paul J. ; Lin, Hung Yun ; Sudha, Thangirala ; Yalcin, Murat ; Tang, Heng Yuan ; Hercbergs, Aleck ; Leith, John T. ; Luidens, Mary K. ; Ashur-Fabian, Osnat ; Incerpi, Sandra ; Mousa, Shaker A. / Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. In: OncoTargets and Therapy. 2014 ; Vol. 7. pp. 1619-1624.
@article{0fc46c4cfb2c47ce8cb440d3c45e7495,
title = "Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis",
abstract = "The extracellular domain of integrin avB3 contains a receptor for thyroid hormone and hormone analogs. The integrin is amply expressed by tumor cells and dividing blood vessel cells. The proangiogenic properties of thyroid hormone and the capacity of the hormone to promote cancer cell proliferation are functions regulated nongenomically by the hormone receptor on avB3. An L-thyroxine (T4) analog, tetraiodothyroacetic acid (tetrac), blocks binding of T4 and 3,5,3'-triiodo-L-thyronine (T3) by avB3 and inhibits angiogenic activity of thyroid hormone. Covalently bound to a 200 nm nanoparticle that limits its activity to the cell exterior, tetrac reformulated as Nanotetrac has additional effects mediated by avB3 beyond the inhibition of binding of T4 and T3 to the integrin. These actions of Nanotetrac include disruption of transcription of cell survival pathway genes, promotion of apoptosis by multiple mechanisms, and interruption of repair of double-strand deoxyribonucleic acid breaks caused by irradiation of cells. Among the genes whose expression is suppressed by Nanotetrac are EGFR, VEGFA, multiple cyclins, catenins, and multiple cytokines. Nanotetrac has been effective as a chemotherapeutic agent in preclinical studies of human cancer xenografts. The low concentrations of avB3 on the surface of quiescent nonmalignant cells have minimized toxicity of the agent in animal studies.",
keywords = "Antiangiogenesis, Integrin, Proapoptosis, Thyroid hormone, Thyroxine",
author = "Davis, {Paul J.} and Lin, {Hung Yun} and Thangirala Sudha and Murat Yalcin and Tang, {Heng Yuan} and Aleck Hercbergs and Leith, {John T.} and Luidens, {Mary K.} and Osnat Ashur-Fabian and Sandra Incerpi and Mousa, {Shaker A.}",
year = "2014",
doi = "10.2147/OTT.S67393",
language = "English",
volume = "7",
pages = "1619--1624",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis

AU - Davis, Paul J.

AU - Lin, Hung Yun

AU - Sudha, Thangirala

AU - Yalcin, Murat

AU - Tang, Heng Yuan

AU - Hercbergs, Aleck

AU - Leith, John T.

AU - Luidens, Mary K.

AU - Ashur-Fabian, Osnat

AU - Incerpi, Sandra

AU - Mousa, Shaker A.

PY - 2014

Y1 - 2014

N2 - The extracellular domain of integrin avB3 contains a receptor for thyroid hormone and hormone analogs. The integrin is amply expressed by tumor cells and dividing blood vessel cells. The proangiogenic properties of thyroid hormone and the capacity of the hormone to promote cancer cell proliferation are functions regulated nongenomically by the hormone receptor on avB3. An L-thyroxine (T4) analog, tetraiodothyroacetic acid (tetrac), blocks binding of T4 and 3,5,3'-triiodo-L-thyronine (T3) by avB3 and inhibits angiogenic activity of thyroid hormone. Covalently bound to a 200 nm nanoparticle that limits its activity to the cell exterior, tetrac reformulated as Nanotetrac has additional effects mediated by avB3 beyond the inhibition of binding of T4 and T3 to the integrin. These actions of Nanotetrac include disruption of transcription of cell survival pathway genes, promotion of apoptosis by multiple mechanisms, and interruption of repair of double-strand deoxyribonucleic acid breaks caused by irradiation of cells. Among the genes whose expression is suppressed by Nanotetrac are EGFR, VEGFA, multiple cyclins, catenins, and multiple cytokines. Nanotetrac has been effective as a chemotherapeutic agent in preclinical studies of human cancer xenografts. The low concentrations of avB3 on the surface of quiescent nonmalignant cells have minimized toxicity of the agent in animal studies.

AB - The extracellular domain of integrin avB3 contains a receptor for thyroid hormone and hormone analogs. The integrin is amply expressed by tumor cells and dividing blood vessel cells. The proangiogenic properties of thyroid hormone and the capacity of the hormone to promote cancer cell proliferation are functions regulated nongenomically by the hormone receptor on avB3. An L-thyroxine (T4) analog, tetraiodothyroacetic acid (tetrac), blocks binding of T4 and 3,5,3'-triiodo-L-thyronine (T3) by avB3 and inhibits angiogenic activity of thyroid hormone. Covalently bound to a 200 nm nanoparticle that limits its activity to the cell exterior, tetrac reformulated as Nanotetrac has additional effects mediated by avB3 beyond the inhibition of binding of T4 and T3 to the integrin. These actions of Nanotetrac include disruption of transcription of cell survival pathway genes, promotion of apoptosis by multiple mechanisms, and interruption of repair of double-strand deoxyribonucleic acid breaks caused by irradiation of cells. Among the genes whose expression is suppressed by Nanotetrac are EGFR, VEGFA, multiple cyclins, catenins, and multiple cytokines. Nanotetrac has been effective as a chemotherapeutic agent in preclinical studies of human cancer xenografts. The low concentrations of avB3 on the surface of quiescent nonmalignant cells have minimized toxicity of the agent in animal studies.

KW - Antiangiogenesis

KW - Integrin

KW - Proapoptosis

KW - Thyroid hormone

KW - Thyroxine

UR - http://www.scopus.com/inward/record.url?scp=84907217881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907217881&partnerID=8YFLogxK

U2 - 10.2147/OTT.S67393

DO - 10.2147/OTT.S67393

M3 - Review article

AN - SCOPUS:84907217881

VL - 7

SP - 1619

EP - 1624

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -